Text

MSK CARE TO MEET YOUR CLIENTS’ NEEDS

HELP YOUR CLIENTS GET OVER 3:1 ROI ON INNOVATIVE MUSCULOSKELETAL CARE

WHAT IF YOU COULD OFFER A PROVEN SOLUTION THAT CUTS COSTS WHILE BOOSTING EMPLOYEE SATISFACTION?

Learn More

A GAME-CHANGER FOR YOUR CLIENTS: APOS®

PROVEN THROUGH REAL-WORLD CLAIMS DATA ACROSS MEDICAID, MEDICARE ADVANTAGE, AND COMMERCIAL POPULATIONS, APOS® CONSISTENTLY DELIVERS:

  • More than 3:1 ROI within the first year of implementation
  • Reduced need for high-cost interventions like surgeries and injections
  • Up to 89% reduction in the need for total knee replacement surgery
  • Average savings of $3,689 per patient, significantly lowering healthcare expenses
Contact Us

APOS® IS PRECISION MEDICINE FOR MUSCULOSKELETAL CONDITIONS

  • Apos® offers a targeted solution for chronic knee, hip, and back conditions.
  • By considering each patient’s unique anatomy, biomechanics, neuromuscular responses, and medical history, Apos® delivers personalized treatment tailored to individual needs.
  • As simple as putting on reading glasses, it provides pain relief and improves function and quality of life.

AFTER TREATMENT, APOS® PATIENTS…

HAVE​

60
%

BETTER FUNCTION1
(ON AVERAGE)

EXPERIENCE​

70
%

LESS PAIN1
(ON AVERAGE)​

REPORT A

96
%

SATISFACTION
RATE2

CAN WALK​

13
%

FASTER3

USE

58
%

LESS
PAINKILLERS4

Unlike traditional methods, we use advanced gait science to retrain how you walk, treating both the symptoms and the underlying causes of pain, all in the comfort of your home.

WHAT DOES THIS MEAN FOR YOUR CLIENTS?

  • EMPLOYEE RETENTION
    Reduced absenteeism and improved well-being translate into more productive employees and higher retention rates.
  • LONG-TERM IMPACT
    Studies have shown that Apos® helps reduce the need for surgery for at least six years, preventing lengthy recovery and minimizing downtime.
  • EASY TO IMPLEMENT
    Seamless integration with minimal management for benefits administrators.

SET YOURSELF APART AS A CONSULTANT AND MAKE A REAL DIFFERENCE IN YOUR CLIENTS’ MSK CARE STRATEGIES

Contact Us

CHOOSE AN MSK SOLUTION THAT’S MEANINGFUL FOR YOU AND YOUR CLIENTS

CONTACT US TO IMPROVE YOUR MSK RESULTS WHILE REDUCING COSTS

As Featured In

publications m gray

AWARDS AND APPROVALS

stamp fda
stamp ce
stamp pbgh
stamp eular
stamp evidence based
stamp ghp
stamp nice
stamp ie 100
gra
ny100
world future awards 2025

FAQs

Apos® reduces the need for expensive surgeries, injections, and treatments while improving employee health, leading to fewer missed workdays and higher productivity. A recent study showed 43% reduction in MSK management costs within one year of implementation.

Unlike traditional approaches, Apos® uses advanced gait science to retrain how patients walk, addressing both the symptoms and underlying causes of pain—all from the comfort of home or the office.

Our approach is backed by over 70 peer-reviewed clinical publications, including a recent study showing that 89% of eligible total knee replacement patients avoided surgery for up to 6 years with Apos®.

Apos® is FDA cleared for the treatment of knee osteoarthritis (OA) and is FDA-registered with evidence supporting its use for chronic hip pain and non-specific low back pain. It provides personalized treatment tailored to each patient’s unique needs.

Many feel relief right away as the footwear helps realign their joints. For others, it may take 3-6 months. Long-term relief happens because, over time, the muscles learn to stabilize the joints better, even when they are not wearing the footwear.

Yes, studies show that Apos® can reduce the need for total knee replacement surgery by up to 89%.4

SOURCES

  1. Reichenbach et al., JAMA (2020): 70% pain reduction with Apos® vs. 35% in controls.
  2. NHS UK survey: 98% would recommend Apos®.
  3. Sorin, A., et al. (2020). BMC Musculoskelet Disord. 21:846.
  4. Bar-Ziv Y, et al. (2010). BMC Musculoskelet Disord. 11:179.
  5. J Health Econ Outcomes Res. 2024 May 16;11(1):134-140. doi: 10.36469/001c.117155. eCollection 2024.
  6. Benn R, Rawson L, Phillips A. Utilising a non-surgical intervention in the knee osteoarthritis care pathway: a 6-year retrospective audit on NHS patients. Therapeutic Advances in Musculoskeletal Disease. 2023;15.